Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms
  • Receptor, Epidermal Growth Factor

abstract

  • p21 expression in colorectal cancer, especially in combination with p53 mutation, is a predictor of resistance to the combination chemotherapy with gefitinib. Activating EGFR mutations are rare in colorectal cancer and do not seem to confer sensitivity to gefitinib and chemotherapy.

publication date

  • September 15, 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-05-0738

PubMed ID

  • 16166444

Additional Document Info

start page

  • 6650

end page

  • 6

volume

  • 11

number

  • 18